Literature DB >> 382750

Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study.

O Bratfos, J O Haug.   

Abstract

In a material of 71 patients admitted because of acute or chronic psychoses, 32 were treated with sulpiride (up to 1,800 mg per day) and 39 with chlorpromazine (up to 675 mg). Duration of treatment was from 4 to 8 weeks. The effect of the two preparations was very similar as were the type and frequency of side effects, except that sulpiride did not cause sunrash.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 382750     DOI: 10.1111/j.1600-0447.1979.tb00259.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

1.  BRL 20596, a novel anilide with central dopamine antagonist activity.

Authors:  W Campbell; M S Clark; P J Mitchell; P L Needham; J M Semple
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up.

Authors:  M Capecci; R A Ricciuti; D Burini; V G Bombace; L Provinciali; M Iacoangeli; M Scerrati; M G Ceravolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

Review 3.  A risk-benefit assessment of sulpiride in the treatment of schizophrenia.

Authors:  M C Mauri; S Bravin; A Bitetto; R Rudelli; G Invernizzi
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 4.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

5.  Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysis.

Authors:  Edward Chia-Cheng Lai; Cheng-Yang Hsieh; Yea-Huei Kao Yang; Swu-Jane Lin
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.